Strategic Vaccines – Landscape & Forecast – Disease Landscape & Forecast (G7)

Vaccination programs have had a transformative impact on global public health, significantly reducing the burden of infectious diseases, lowering mortality, and improving quality of life worldwide. Individuals benefit from a broad range of vaccines across their lifespans, protecting against infections and associated complications. Advances in vaccine technologies, including mRNA and other novel platforms, continue to expand the potential for vaccines that offer enhanced specificity, improved immunogenicity, and more practical deployment. Both the adult and paediatric segments of the vaccine market remain attractive for the development of new prophylactic options. This report focuses on the following key infectious diseases: human papillomavirus (HPV), herpes zoster virus (HZ), hepatitis B virus (HBV), meningococcus, pneumococcus, seasonal influenza, respiratory syncytial virus (RSV), and COVID-19. Leading vaccines and major market players include Pfizer (Comirnaty, Abrysvo, Prevnar 13), GSK (Shingrix, Menveo, Arexvy), Sanofi (Fluzone, MenQuadfi), Merck (Gardasil, Pneumovax 23), and Moderna (Spikevax, mRESVIA, mNEXSPIKE). Expanding immunization practices and ongoing innovation are set to drive sustained growth across these therapeutic areas.

Questions answered

• What are the sizes of the populations eligible for key vaccination programs in the G7?
• What are the key drivers of brand preference in each vaccine market?
• How will the current vaccine pipeline fulfill areas of unmet need?
• How will key current and emerging vaccines perform commercially?
• How has the role and uptake of existing vaccines evolved in response to changing immunization landscape?

Geographies: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading infectious disease specialists. Survey data collected for this and other Clarivate research

Epidemiology: Vaccine-eligible pool by country, segmented by key infectious diseases (HPV, HZ, HBV, meningococcus, pneumococcus, seasonal influenza, RSV, and COVID-19)

Forecast: 10-year, annualized, drug-level sales and patient share of key vaccines through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging vaccines, and vaccine forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.